Hans Bickel

This inventor holds 41 USPTO granted patents, primarily in Cephalosporin Compounds. Top assignees: Ciba-Geigy Corporation, Fujisawa Pharmaceutical Company, Ltd.. Active years: 1976-1988.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans Bickel. Retrieved from https://idiyas.com/inventor/hans-bickel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 41

% Patents Active = 100.0

Average Co-Inventor Count = 2.3

ph-index = 8

Forward Citations = 227(Granted Patents)

Location History:

Binningen, CH (1976 - 1987)
Binnegen, CH (1988)

Company Filing History:

40 out of 6,858

Ciba-Geigy Corporation

patents

1 out of 940

Fujisawa Pharmaceutical Company, Ltd.

patents

Years Active: 1976-1988

Loading Chart...

Areas of Expertise:

Cephalosporin

Enol Derivatives

Rifamycin

Cephem Compounds

Antibiotic Derivatives

Aminoethyl Compounds

Carbonylmethyl Derivatives

Pharmaceutical Composition

Thia Bicyclic Compounds

Acylaminoacetic Acid

Mercaptoalcohols

Substituted Derivatives

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4735937 - 8-oxo-5-thia-1-azabicyclo(4,2,0)oct-2-ene compounds (1988-04-05),

2. 4668781 - Ceph-3-one compounds and process for their manufacture (1987-05-26),

3. 4591642 - Cephem and cepham derivatives (1986-05-27),

4. 4579684 - Process for the manufacture of enol derivatives (1986-04-01),

5. 4550162 - Process for the manufacture of enol derivatives (1985-10-29),

6. 4477658 - Process for the preparation of cepham and cephem compounds (1984-10-16),

7. 4458069 - Cephalosporin compounds (1984-07-03),

8. 4434287 - Cephalosporin derivatives (1984-02-28),

9. 4430498 - 8-Oxo-5-thia-1-azabicyclo(4,2,0)oct-2-ene compounds (1984-02-07),

10. 4405778 - Process for preparing cephalosporin ethers (1983-09-20),

11. 4389524 - Cepham compounds (1983-06-21),

12. 4353826 - Substituted rifamycins (1982-10-12),

13. 4319027 - Process for the manufacture of ceohem enol derivatives (1982-03-09),

14. 4301278 - Process for the manufacture of enol derivatives (1981-11-17),

15. 4293462 - Process for the manufacture of enol derivatives, and intermediates (1981-10-06),

Of course! Here is the article you requested:

Title: The Innovative Legacy of Inventor Hans Bickel from Binningen, CH

Introduction:

Hans Bickel, a pioneering inventor hailing from Binningen, CH, has carved a distinguished path in the world of innovation with his groundbreaking inventions and unwavering dedication to technological advancement.

Latest Patents:

With a remarkable portfolio boasting 41 patents, Hans Bickel's latest inventions include:

1. 8-oxo-5-thia-1-azabicyclo(4,2,0)oct-2-ene compounds: Antibiotic compounds with exceptional properties.

2. Ceph-3-one compounds and process for their manufacture: Precursors with outstanding pharmacological effects.

Career Highlights:

Having contributed significantly to the industry, Hans Bickel has left an indelible mark through his inventive spirit and remarkable patents. Notable companies he has collaborated with include:

1. Ciba-Geigy Corporation (CIBA)

2. Fujisawa Pharmaceutical Company, Ltd.

Collaborations:

Throughout his illustrious career, Hans Bickel has worked alongside esteemed coworkers such as Heinrich H Peter and Riccardo Scartazzini, further enriching his innovative pursuits through fruitful collaborations.

Conclusion:

In conclusion, Hans Bickel stands as a beacon of innovation, with a remarkable career marked by groundbreaking inventions and a relentless pursuit of technological advancement. His contributions have not only shaped the industry but have also inspired future generations of inventors.

I hope this article meets your expectations! If you require any further modifications or additional information, feel free to let me know.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]